FPRX Five Prime Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

FPRX [NASD]

Five Prime Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.97	Insider Own	0.30%	Shs Outstand	35.43M	Perf Week	-11.11%
Market Cap	175.24M	Forward P/E	-	EPS next Y	-2.13	Insider Trans	-	Shs Float	35.29M	Perf Month	6.55%
Income	-104.50M	PEG	-	EPS next Q	-0.60	Inst Own	73.90%	Short Float	4.85%	Perf Quarter	-14.98%
Sales	18.00M	P/S	9.74	EPS this Y	5.10%	Inst Trans	-1.96%	Short Ratio	5.04	Perf Half Y	48.78%
Book/sh	3.39	P/B	1.44	EPS next Y	5.40%	ROA	-48.00%	Target Price	8.83	Perf Year	25.77%
Cash/sh	3.54	P/C	1.38	EPS next 5Y	-	ROE	-71.60%	52W Range	1.75 - 7.34	Perf YTD	6.32%
Dividend	-	P/FCF	-	EPS past 5Y	-16.90%	ROI	-94.30%	52W High	-33.51%	Beta	1.92
Dividend %	-	Quick Ratio	6.70	Sales past 5Y	-5.00%	Gross Margin	-	52W Low	178.86%	ATR	0.41
Employees	87	Current Ratio	6.70	Sales Q/Q	3.00%	Oper. Margin	-	RSI (14)	42.68	Volatility	6.17% 7.93%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	51.50%	Profit Margin	-	Rel Volume	0.98	Prev Close	5.52
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	339.56K	Price	4.88
Recom	2.00	SMA20	-10.68%	SMA50	3.25%	SMA200	6.96%	Volume	333,955	Change	-11.59%

Sep-22-20

Upgrade

Guggenheim

Neutral → Buy

$11

Jun-22-20

Upgrade

Wedbush

Neutral → Outperform

$5 → $9

Feb-28-20

Downgrade

JP Morgan

Neutral → Underweight

Feb-18-20

Downgrade

Wedbush

Outperform → Neutral

Nov-20-19

Resumed

Guggenheim

Neutral

Oct-01-19

Downgrade

Guggenheim

Buy → Neutral

Jun-03-19

Downgrade

Wells Fargo

Outperform → Market Perform

May-29-19

Initiated

ROTH Capital

Neutral

$10

Apr-12-19

Resumed

Guggenheim

Buy

$24

Sep-13-18

Resumed

Leerink Partners

Outperform

$24

Jun-28-18

Initiated

Raymond James

Mkt Perform

Jun-15-18

Initiated

JP Morgan

Neutral

$19

May-18-18

Initiated

Wedbush

Neutral

Nov-06-17

Reiterated

RBC Capital Mkts

Outperform

$41 → $50

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$41

Mar-02-17

Initiated

Instinet

Buy

$94

Oct-25-16

Initiated

Citigroup

Buy

Jan-21-16

Initiated

Credit Suisse

Outperform

Dec-04-15

Resumed

Wells Fargo

Outperform

Oct-19-15

Reiterated

Oppenheimer

Outperform

$45 → $48

Oct-28-20 12:32PM	Will Five Prime Therapeutics (FPRX) Report Negative Q3 Earnings? What You Should Know Zacks -11.59%
Oct-27-20 10:29PM	Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call Business Wire
Oct-13-20 02:47PM	Hedge Funds Are Coming Back To Five Prime Therapeutics Inc (FPRX) Insider Monkey
Oct-12-20 08:48AM	Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session Zacks +13.20%
Oct-09-20 09:50AM	Reflecting on Five Prime Therapeutics' (NASDAQ:FPRX) Share Price Returns Over The Last Three Years Simply Wall St. +5.08%
Sep-22-20 09:36AM	Benzinga's Top Upgrades, Downgrades For September 22, 2020 Benzinga
Sep-09-20 06:30PM	Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference Business Wire
Aug-13-20 03:30PM	Wedbush: 3 Healthcare Stocks Under $10 With Massive Upside Ahead TipRanks
Aug-10-20 12:56PM	Do Institutions Own Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares? Simply Wall St. -8.01%
12:55PM	What Type Of Shareholders Own The Most Number of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares? Simply Wall St.
Aug-06-20 08:30PM	Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Five Prime Therapeutics Reports Second Quarter 2020 Results Business Wire
Jul-30-20 12:33PM	Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +6.30%
Jul-29-20 07:00PM	Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
06:30PM	Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call Business Wire
12:33PM	Will Five Prime Therapeutics (FPRX) Report Negative Q2 Earnings? What You Should Know Zacks
Jun-26-20 09:17AM	Is Five Prime Therapeutics Inc (FPRX) Going to Burn These Hedge Funds? Insider Monkey
Jun-22-20 10:48AM	Why Five Prime's Stock Is Trading Higher Today Benzinga +45.39%
Jun-11-20 07:53AM	Edited Transcript of FPRX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents +7.04%
May-15-20 09:37AM	Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now? Zacks
May-10-20 09:55AM	Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
May-07-20 04:05PM	Five Prime Therapeutics Reports First Quarter 2020 Results Business Wire +11.14%
Apr-30-20 04:05PM	Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call Business Wire
Apr-22-20 04:05PM	Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format Business Wire
Apr-14-20 09:00AM	Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer Business Wire +7.35%
Apr-09-20 07:35AM	Here's Why Five Prime Therapeutics (NASDAQ:FPRX) Must Use Its Cash Wisely Simply Wall St. +10.20%
Mar-20-20 03:32AM	Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-13-20 09:25AM	Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology Business Wire
Feb-27-20 05:45PM	Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates Zacks -10.56%
Feb-25-20 04:22PM	Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire -7.24%
Feb-20-20 12:31PM	Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-19-20 09:25AM	Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs Business Wire +18.33%
Feb-18-20 09:25AM	Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer Business Wire
Feb-13-20 04:05PM	Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call Business Wire -8.11%
Jan-10-20 09:28AM	If You Had Bought Five Prime Therapeutics (NASDAQ:FPRX) Stock Three Years Ago, You'd Be Sitting On A 89% Loss, Today Simply Wall St. -6.00%
Dec-30-19 01:05PM	Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-19 02:26PM	Longtime biotech exec walks away from board to concentrate on startup American City Business Journals
Dec-26-19 04:05PM	Five Prime Therapeutics Announces Resignation of Dr. Lewis T. "Rusty" Williams From Board of Directors Business Wire
Dec-20-19 01:54PM	Head of big South San Francisco biotech thriving in first CEO role American City Business Journals
Dec-16-19 06:17PM	Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents -5.80%
Dec-10-19 11:14AM	Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy ? Insider Monkey +5.14%
Nov-09-19 07:00AM	Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting Business Wire
Nov-08-19 01:02PM	Insiders Roundup: Crocs, OPKO Health GuruFocus.com
Nov-06-19 06:45PM	Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Five Prime Therapeutics Reports Third Quarter 2019 Results Business Wire
Oct-30-19 10:33AM	Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-24-19 04:01PM	Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call Business Wire
Oct-11-19 04:04PM	Insiders Roundup: Facebook, American Defense Systems GuruFocus.com
08:14AM	The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 09:57PM	South San Francisco biotech to cut another 70 jobs, may sublease space American City Business Journals
04:01PM	Five Prime Announces Restructuring Business Wire
Oct-02-19 07:30AM	Looking for 1,600% Returns? Biotech Has No Shortage of Analyst Optimism Bloomberg +5.15%
Sep-30-19 03:01AM	Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress Business Wire -9.36%
Sep-20-19 09:59AM	Peninsula biotech CEO resigns in latest corner office switch American City Business Journals
Sep-19-19 04:05PM	Five Prime Therapeutics Announces Management Transition Business Wire
12:18PM	What Kind Of Shareholder Owns Most Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock? Simply Wall St.
Aug-22-19 07:45PM	Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire
Aug-15-19 10:16PM	Edited Transcript of FPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 06:25PM	Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Five Prime Therapeutics Reports Second Quarter 2019 Results Business Wire
Aug-01-19 03:06PM	Cancer-fighting Peninsula company postpones $92 million IPO American City Business Journals
Jun-25-19 11:56AM	Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Simply Wall St.
Jun-24-19 04:05PM	Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors Business Wire
01:28PM	Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy? Insider Monkey
Jun-18-19 08:50AM	Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session Zacks
Jun-09-19 03:05PM	Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors Business Wire
03:00PM	Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire
Jun-01-19 09:01AM	Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting Business Wire
May-24-19 04:01PM	Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire
May-17-19 12:45PM	Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-15-19 06:39PM	Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors Business Wire
05:45PM	Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting Business Wire
May-09-19 11:23AM	Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript Motley Fool -5.03%
May-08-19 06:45PM	Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:39PM	Five Prime Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM	Five Prime Therapeutics Reports First Quarter 2019 Results Business Wire
May-01-19 10:33AM	Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline Zacks
Apr-30-19 09:04AM	Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO? American City Business Journals -7.20%
Apr-17-19 07:56PM	Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8 Business Wire
01:27PM	What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory? Simply Wall St.
Mar-25-19 09:19AM	Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-20-19 02:09PM	Edited Transcript of FPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-19-19 09:28AM	Will Five Prime Therapeutics Continue to Surge Higher? Zacks
Mar-11-19 06:00AM	Five Prime Has 5 Drugs in its Pipeline MoneyShow
Mar-05-19 06:05PM	Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference Business Wire
Feb-26-19 09:47PM	Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM	Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-20-19 08:05PM	Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150 Business Wire
Feb-07-19 04:05PM	Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26 Business Wire
Feb-04-19 05:05PM	Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum Business Wire
Jan-30-19 11:45PM	Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals
Jan-28-19 09:37AM	MacroGenics Up on Lifting of Partial Hold on Cancer Candidate Zacks -8.42%
Jan-24-19 03:13AM	Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue? Zacks
Jan-17-19 02:05PM	Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium Business Wire +5.98%
Jan-16-19 07:40AM	Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-15-19 05:08PM	Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line American City Business Journals +9.40%
04:05PM	Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities Business Wire
Jan-14-19 06:41PM	Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium Business Wire
Jan-13-19 03:50PM	The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-12-18 04:05PM	Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BVF PARTNERS L P/IL	10% Owner	Oct 06	Buy	5.04	345,241	1,738,288	4,336,875	Oct 08 05:27 PM
BVF PARTNERS L P/IL	10% Owner	Sep 22	Buy	3.80	32	122	541,116	Sep 24 07:49 PM
BVF PARTNERS L P/IL	10% Owner	May 14	Buy	4.10	293,587	1,203,707	4,179,093	May 18 08:02 PM
BVF PARTNERS L P/IL	10% Owner	Dec 20	Buy	4.05	515,020	2,085,831	3,929,792	Dec 26 05:59 PM
BVF PARTNERS L P/IL	10% Owner	Dec 09	Buy	4.02	135,000	542,363	3,648,474	Dec 11 06:13 PM
BERGER FRANKLIN M	Director	Dec 03	Sale	4.00	47,890	191,560	5,000	Dec 04 06:28 PM
BERGER FRANKLIN M	Director	Dec 02	Sale	3.92	32,090	125,793	52,890	Dec 04 06:28 PM
BVF PARTNERS L P/IL	10% Owner	Nov 22	Buy	3.40	1,120,010	3,808,146	3,534,600	Nov 26 05:59 PM
BVF PARTNERS L P/IL	10% Owner	Nov 05	Buy	4.00	968,112	3,872,448	2,958,503	Nov 07 07:22 PM
BVF PARTNERS L P/IL	10% Owner	Oct 31	Buy	3.85	6,833	26,304	2,461,782	Oct 31 06:24 PM
BVF PARTNERS L P/IL	10% Owner	Oct 30	Buy	3.89	20,081	78,157	2,458,366	Oct 31 06:24 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience